Potent aza-peptide derived inhibitors of HCV NS3 protease
摘要:
Chronic hepatitis C infection is the primary cause for cirrhosis of the liver and hepatocellular carcinoma leading to liver failure and transplantation. The etiological agent hepatitis C virus produces a single positive strand RNA that is processed further with the help of NS3 serine protease to produce mature virus. Inhibition of this protease can potentially be used to develop drugs for HCV infections. Boceprevir is a ketoamide derived novel inhibitor of HCV NS3 protease that has been progressed to clinical trials and proven to be efficacious in humans. Herein, we report our efforts in identifying an aza-peptide derivative as a potential second generation compound, that lacks electrophilic ketoamide group and are potent in enzyme and replicon assay. (C) 2009 Published by Elsevier Ltd.
[EN] HYDRAZIDO-PEPTIDES AS INHIBITORS OF HCV NS3-PROTEASE<br/>[FR] PEPTIDES HYDRAZIDO EN TANT QU'INHIBITEURS DE LA PROTÉASE NS3 DU HCV
申请人:SCHERING CORP
公开号:WO2008118332A2
公开(公告)日:2008-10-02
[EN] The present invention discloses novel compounds, which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. [FR] La présente invention concerne de nouveaux composés ayant une activité inhibitrice de la protéase du HCV ainsi que des procédés pour les préparer. Dans un autre mode de réalisation, l'invention décrit des compositions pharmaceutiques comprenant ces composés ainsi que leurs procédés d'utilisation pour traiter les troubles associés à la protéase du HCV.